InflaRx N.V. IFRX 深 沪
交易中 07-01 11:05:43 美东时间
2.355
+0.115
+5.13%
华盛通- 最 高2.405
- 今 开2.24
- 成交量 32.79万股
- 最 低 2.17
- 昨 收 2.24
- 总市值 3.47亿
- 52周最高 2.9489
- 市盈率 静 --
- 换手率 0.22%
- 52周最低 0.7406
- 委 比 -46.40%
- 总股本 1.47亿
- 历史最高 53.10
- 量 比 0.73
- 振 幅 10.49%
- 历史最低 0.7113
- 每 手 1
- 风险率 0.47%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多InflaRx Mulls Feasibility For AAV In Europe
InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced it is assessing the feasibility of broadening its development and registrational strategy for AAV in Europe. The company has initiated this assessmen...
06-30 19:37
美股大行评级 | 潜在涨幅257.14%！瑞杰金融上调InflaRx目标价至9美元，评级升至"强烈买入"
今日重点评级关注：瑞杰金融：上调InflaRx评级至"强烈买入"，目标价从7美元升至9美元；巴克莱：维持Orchestra BioMed Hldgs"超配"评级，目标价从12美元升至13美元
05-14 14:32
美股大行评级 | Arxis、Madison Air获多家大行首予买入评价！潜在涨幅441.87%！Caribou Biosciences获HC Wainwright & Co.升目标价至11美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Caribou Biosciences"买入"评级，目标价从9美元升至11美元；康托·菲茨杰拉德：维持Artiva Biotherapeutics"超配"评级，目标价从10美元升至40美元
05-12 12:36
Cantor Fitzgerald Maintains Overweight on InflaRx, Raises Price Target to $4
Cantor Fitzgerald analyst Steve Seedhouse maintains InflaRx (NASDAQ:IFRX) with a Overweight and raises the price target from $2 to $4.
05-11 21:47
美股牛股 | 伟创力绩后暴涨近40%！NNE大涨27%，与超微电脑联手探索核能AI数据中心
伟创力绩后暴涨近40%！宣布分拆云计算部门独立上市；NNE大涨27%，与超微电脑联手探索核能AI数据中心>>
05-07 19:09
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers GlucoTrack (NASDAQ:GCTK) stock increased by 39.7% to $1.02 during Wedn...
05-07 01:05
InflaRx Prices Underwritten Offering of 75M Shares At $2.00 Per Share
All ordinary shares in the offering are being sold by the Company. The offering is expected to close on May 7, 2026, subject to the satisfaction of customary closing conditions.The Company intends to use the net proceeds
05-06 20:34
InflaRx regains Nasdaq compliance after shares trade above $1
InflaRx N.V. on Tuesday said it had regained compliance with Nasdaq’s minimum bid price requirement, after its shares closed at or above $1.00 for 10 consecutive business days between April 13 and Apr...
04-28 19:53
InflaRx Regains Nasdaq Compliance
InflaRx N.V. (NASDAQ:IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system (the "Company"), today announced that it has received a written notice (the "Notice"),
04-28 19:33
